Anti-psychotic Medication (New Use) Weight Loss Study

Surveillance Study of Weight Response and Body Composition in Subjects Who Are First-Time Users (Less Than 3 Months) of the Following Medications: Risperdal, Seroquel, and/or Zyprexa, in Combination With 500 mg IHBG-10 TID

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01272752

Enrollment

Registered

2011-01-10

Start date

2013-04-30

Completion date

2013-12-31

Last updated

2012-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, weight loss, weight management, anti-psychotic medication, nutriceutical

Brief summary

This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have just started taking (for less than three months) certain anti-psychotic medications (Risperdal, Seroquel, and/or Zyprexa).

Detailed description

A total of 30 subjects will be enrolled in this study. They will be randomized in to one of two groups. One group (of 20 subjects) will take 500 mg of the investigational product (IHBG-10) 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. The other group (of 10 subjects) will take a placebo 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. Subjects will take the investigational product or placebo for 12 weeks. Participation in this study involves 4 study visits.

Interventions

DIETARY_SUPPLEMENTIHBG-10

500 mg IHBG-10

DIETARY_SUPPLEMENTPlacebo

Placebo taken 15 minutes prior to the three main meals of the day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men and women, age 18 and older * Agree to keep diet, exercise and all current health habits stable during participation in the study * Have been taking Risperdal (Risperidone), Seroquel (Quetiapine), or Zyprexa (Olanzapine) for less than 3 months

Exclusion criteria

* Current active acute psychotic episode * Women who are pregnant, breastfeeding or planning to become pregnant * Prior bariatric surgery * Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month * Obesity as a result of a clinically-diagnosed endocrine problem

Design outcomes

Primary

Measure	Time frame
Weight	12 weeks

Secondary

Measure	Time frame
Body composition	12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026